Intraarterial Dexamethasone for Pain Relief After Uterine Fibroid Embolization: A Randomized Clinical Trial

Area of Science:

• Interventional Radiology
• Vascular Interventional Radiology
• Gynecologic Procedures

Background:

• Acute postprocedural pain is a significant challenge following uterine fibroid embolization (UFE).
• Effective pain management strategies are crucial for improving patient outcomes and adherence to UFE as a treatment option.

Purpose of the Study:

• To evaluate the efficacy of intraarterial dexamethasone in reducing acute postprocedural pain after UFE.
• To assess the impact of intraarterial dexamethasone on postembolization syndrome and fibroid symptom burden.

Main Methods:

• A double-blind, placebo-controlled randomized clinical trial involving 40 women undergoing UFE.
• Participants received either intraarterial dexamethasone (10 mg) or saline placebo during the embolization procedure.
• Pain scores were assessed for up to 168 hours post-procedure; quality of life and fibroid volume were evaluated at 1 and 3 months.

Main Results:

• Intraarterial dexamethasone significantly reduced mean pain scores immediately post-procedure (P=.04) and through 96 hours (P=.02) compared to placebo.
• Mean pain scores over 168 hours were significantly lower in the dexamethasone group (P=.02).
• No significant differences in fibroid volume reduction or major complications were observed between groups.

Conclusions:

• Intraarterial dexamethasone effectively reduces postprocedural pain following UFE without compromising treatment efficacy or safety.
• This intervention presents a simple, low-cost method to alleviate pain and reduce the need for analgesics in patients undergoing UFE.